Clinical Experiences of Coronary MAC (Maximum Arterial Re-Creation) Stent.
10.4070/kcj.1998.28.10.1700
- Author:
Sung Hee KIM
;
Myung Ho JEONG
;
Yang Soo JANG
;
Youl BAE
;
Joon Woo KIM
;
Jang Hyun CHO
;
Nam Ho KIM
;
Woo Suck PARK
;
Young Keun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
- Publication Type:Clinical Trial ; Original Article
- Keywords:
MAC (Maximum Arterial Re-Creation) stent
- MeSH:
Angina, Unstable;
Angioplasty;
Constriction, Pathologic;
Coronary Angiography;
Coronary Artery Disease;
Coronary Vessels;
Diagnosis;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Jeollanam-do;
Myocardial Infarction;
Myocardial Ischemia;
Phenobarbital;
Stents*;
Thrombosis
- From:Korean Circulation Journal
1998;28(10):1700-1706
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: We previously reported the effects of MAC (Maximum Arterial Re-Creation) stent on stent restenosis in a porcine model. The clinical trial was performed in patients with ischemic heart disease after MAC stent implantation. MATERIALS AND METHOD: We analyzed the clinical and angiographic results in 20 patients in 22 lesions (15 M, 5 F, 59+/-11 year), who underwent MAC stent at Chonnam University Hospital between Nov '97 and Aug '98. Clinical diagnosis was 13 unstable angina (65%), 6 acute myocardial infarction (30%) and 1 old myocardial infarction (5%). RESULTS: Indications for stent were 3 de novo lesion (13.6%), 7 restenosis (31.8%), 8 suboptimal angioplasty result (36.4%) and 4 bail-out procedure (18.2%). Target stented coronary arteries were 15 left anterior descending coronary arteries (67.3%), 2 left circumflex coronary arteries (9.1%) and 5 right coronary arteries (22.7%). Morphologic types were 13 type B1 (59.1%), 5 B2 (22.7%) and 4 C (18.2%). Minimal luminal diameter (MLD) before stent was 0.75+/-0.35 mm and percent diameter stenosis (DS) was 75+/-11.5%, which were improved 2.97+/-0.28 mm in MLD and 2.79+/-5.4% in DS after stent. MAC stent was placed successfully in all patients and one case of acute stent thrombosis was improved after ReoPro infusion. Mean follow-up period was 5.2+/-3.2 months and 100 % event-free survival was observed in all patients. Follow-up coronary angiography was performed in 5 patients and showed no stent restenosis. CONCLUSION: The MAC stent is one of effective and safe devices in the treatment of coronary artery diseases without significant complications and target vessel revascularization.
